Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus MEDLINE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Testing of a bioactive, moldable bone graft substitute in an infected, critically sized segmental defect model.

Title: Testing of a bioactive, moldable bone graft substitute in an infected, critically sized segmental defect model.
Authors: Brown ME; F. Joseph Halcomb III, M.D. Department of Biomedical Engineering, University of Kentucky, Lexington, Kentucky.; Zou Y; F. Joseph Halcomb III, M.D. Department of Biomedical Engineering, University of Kentucky, Lexington, Kentucky.; Peyyala R; Center for Oral Health Research, College of Dentistry, University of Kentucky, Lexington, Kentucky.; Huja SS; Division of Orthodontics, College of Dentistry, University of Kentucky, Lexington, Kentucky.; Cunningham LL; Division of Oral and Maxillofacial Surgery, College of Dentistry, University of Kentucky, Lexington, Kentucky.; Milbrandt TA; Department of Orthopaedic Surgery, University of Kentucky, Lexington, Kentucky.; Dziubla TD; Department of Chemical and Materials Engineering, University of Kentucky, Lexington, Kentucky.; Puleo DA; F. Joseph Halcomb III, M.D. Department of Biomedical Engineering, University of Kentucky, Lexington, Kentucky.
Source: Journal of biomedical materials research. Part B, Applied biomaterials [J Biomed Mater Res B Appl Biomater] 2018 Jul; Vol. 106 (5), pp. 1878-1886. Date of Electronic Publication: 2017 Sep 19.
Publication Type: Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
Language: English
Journal Info: Publisher: John Wiley & Sons Country of Publication: United States NLM ID: 101234238 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1552-4981 (Electronic) Linking ISSN: 15524973 NLM ISO Abbreviation: J Biomed Mater Res B Appl Biomater Subsets: MEDLINE
Imprint Name(s): Original Publication: Hoboken, NJ : John Wiley & Sons, c2003-
MeSH Terms: Bone Substitutes*/chemistry ; Bone Substitutes*/pharmacology ; Calcium Sulfate*/chemistry ; Calcium Sulfate*/pharmacology ; Femur*/injuries ; Femur*/metabolism ; Femur*/microbiology ; Femur*/pathology ; Vancomycin*/chemistry ; Vancomycin*/pharmacology; Infections/microbiology ; Animals ; Infection Control ; Male ; Rats ; Rats, Sprague-Dawley
Abstract: Large infected bone defects, often resulting from high energy traumas, are difficult to treat due to their variability in complexity and location. Standard treatment for infected bone defects begins with a protocol that includes a series of debridements in conjunction with an extended course of systemic antibiotics. Only after the infection has been eliminated will repair of the defect commence, typically with implantation of autologous bone. To address some of the shortcomings of the standard treatment methods, such as serial procedures, limited grafting material, and the need for a second surgical site for autologous bone, a sequential, dual drug-releasing, moldable, calcium sulfate-based bone graft substitute was developed previously. In the present studies, the effectiveness of the material for treating both the infection with vancomycin and bone defect with simvastatin was evaluated in vivo using a critically sized, infected segmental defect model in rat femurs. Although the infection was not fully eliminated, the local release of vancomycin increased survivorship of infected animals by 464% compared to nontreated controls. Infected animals receiving antimicrobial treatment showed comparable amounts of new bone formation within the defect site when compared to noninfected controls. Incorporating agents capable of disrupting established biofilms into bone graft substitutes may enhance effectiveness in treating a biofilm infection within a bone defect. © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 106B: 1878-1886, 2018.; (© 2017 Wiley Periodicals, Inc.)
Contributed Indexing: Keywords: bone graft substitute; calcium sulfate; infection; simvastatin; vancomycin
Substance Nomenclature: 0 (Bone Substitutes); 6Q205EH1VU (Vancomycin); WAT0DDB505 (Calcium Sulfate)
Entry Date(s): Date Created: 20170920 Date Completed: 20190827 Latest Revision: 20200930
Update Code: 20260130
DOI: 10.1002/jbm.b.34001
PMID: 28926192
Database: MEDLINE

Journal Article; Research Support, U.S. Gov't, Non-P.H.S.